Combinatorial and computational approaches in structure-based drug design

Current Opinion in Drug Discovery and Development

Volumn 1, Issue 1, 1998, Pages 16-27

  Kubinyi, Hugo ^a  

^a BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002716825     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Kubinyi H: Structure-based design of enzyme inhibitors and receptor ligands. CurrOpin Drug Design Discov (1998) 1:4-15
2. Gubemator K, Böhm HJ (Eds): Structure-based ligand design. Wüey-VCH, Weinheim (1998). Strategies and several success stories of structure-based and computer-assisted drug design (9 chapters; about 150 pages).
3. Veerapandian P (Ed): Structure-based drug design. Marcel Dekker, New York (1997). Comprehensive overview of the structure-based design of enzyme inhibitors and other protein ligands (22 chapters, 647 pages; about 1700 references).
4. Babine RE, Bender SL: Molecular recognition of proteinligand complexes: applications to drug design. Chem Rev (1997) 97:1359-1472. Impressive, exceHent and comprehensive review of the structurebased design of many different classes of enzyme inhibitors and other protein ligands (538 references).
5. Böhm HJ, Klebe G, Kubinyi H: Wirkstoffdesign. Spektrum Akademischer Verlag, Heidelberg (1996). A German language book on drug research, discussing classical and modern techniques (31 chapters, 599 pages; about 300 pages on rational drug design methodologies and 160 pages on success stories of structure-based and computer-aided design).
6. Laskowski RA, Hutchinson EG, Michie AD, Wallace AC, Jones ML, Thomton JM: PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sei (1997) 22:488-490.
7. The Web page httptfw\vw.biochem.ucl.ac.uk/bsm/pdbsum/allows one to search, view and download protein 3D structures and ligand geometries from the Brookhaven Protein Databank (7,519 entries; effective April 5, 1998), including valuable information, such as active site amino acids, secondary structures, MOLSCRIPTand LIGPLOT diagrams.
8. Salemme FR, Spurtino J, Bone R: Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Structure (1997) 5:319-324.
9. Müller K: On the paradigm shift from rational to random design. JMolStruc (Theochem)(1997) 398-399:467-471.
10. Czamik AW, DeWitt SH (Eds): A practical guide to combinatorial chemistry. American Chemical Society, Washington (1997).
11. Practice-oriented introduction into combinatorial chemistry.
12. Balkenhohl F, von dem Bussche-Hünnefeld C, Lansky A, Zechel C: Combinatorial synthesis of small organic molecules. AngewChem IntEdEngl'(1996) 35:2289-2337.
13. Comprehensive review of synthetic methods and other aspects of combinatorial chemistry, including about 600 references and many practice-oriented comments in footnotes.
14. Pickett SD, Mason, JS, McLay IM: Diversity profiling and design using 3D pharmacophores: pharmacophorederived queries (PDQ).- J Chem In! Comput Sei (1996) 36:1214-1223.
15. Use of three-point pharmacophores for assessing diversity and for combinatorial library design.
16. Matter H: Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J Med Chem (1997)40:1219-1229. 2D fingerprints are suited to handle molecular diversity; atom-pair descriptors or molecular fields correlate molecular diversity m'th biological activities.
17. Pötter T, Matter H: Random or rational design? Evaluation of diverse compound subsets from chemical structure databases. JMedChem (1998) 41:478-488. Describes the selection of diverse subsets based on 2D fingerprints; more stable OSAR models with higher predictive power, compared to randomly chosen subsets, are obtained from subsets with maximum dissimilarity.
18. Good AC, Lewis RA: New methodology for profiling combinatorial libraries and screening sets: cleaning up the design process with HARPick. J Med Chem (1997) 40:3926-3936.
19. Brown RD, Martin YC: Designing combinatorial library mixtures using a genetic algorithm. J Med Chem (1997) 40:2304-2313.
20. Describes the application of a genetic algorithm to optimizing the diversity of libraries while minimizing the effort required to deconvolute the biological hits.
21. Kubinyi H: Similarity and dissimilarity: a medicinal chemist's view. In: 3D QSAR in drug design. Volume 2. LJgand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):225-252.
22. Chaiken IM, Janda, KD (Eds): Molecular diversity and combinatorial chemistry: libraries and drug discovery. American Chemical Society, Washington DC (1996). ACS conference proceedings (27 chapters, many on library design and diversity issues).
23. Gordon EM, Kerwin JF (Eds): Combinatorial chemistry and molecular diversity in drug discovery. John Wiiey & Sons, New York (1998). Covers techniques and tools as well as organizational and strategic questions of combinatorial chemistry (12 chapters).
24. Warr WA: Combinatorial chemistry and molecular diversity. An overview. J Chem Inf Comput Sei (1997) 37:134-140.
25. a. Li J, Murray CW, Waszkowycz B, Young SC: Targeted molecular diversity in drug discovery: integration of structure-based design and combinatorial chemistry.
26. Drug Discovery Today (1998) 3:105-112. b. Pearlman RS, Smith KM: Novel software tools for chemical diversity. In: 3D QSAR in drug design. Volume 2. LJgand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1993):339-353.
27. Gillet VJ, Willett P, Bradshaw J: Identification of biological activity profiles using substructural analysis and genetic algorithms. J Chem Inf Comput Sei (\Q) 38:165-179.
28. Bone R, Salemme FR: The integration of structure-based design and directed combinatorial chemistry for new pharmaceutical discovery. In: Structure-based drug design, Veerapandian P (Ed). Marcel Dekker, New York (1997):525539.
29. Myers PL: Will combinatorial chemistry deliver real medicines? CurrOpin Blotechnol(1997) 8:701-707. Up-to-date review on combinatorial chemistry, with special emphasis on the rational design of libraries (73 references, up to 1997).
30. Dolle RE: Discovery of enzyme inhibitors through combinatorial chemistry. Molecular Diversity (1996) 2:223236. Enzyme inhibitor libraries and biologically active hits from these libraries.
31. Cowley PM, Rees DC: Applications of solid-phase synthesis to drug discovery. CurrMedChem (1997) 4:211-227.
32. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HQ, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD, Cook JJ, Holahan MA, Stranieri MT, Lynch Jr JJ, Un JH, Chen IW, Vastag K, Naylor-Olsen AM, Vacca JP: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)-propyl trans-4aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem (1998) 41:401-406.
33. Solid phase synthesis of a structurally diverse set 200 amides, selected from > 2,200 acid components.
34. Lumma Jr WC, Witherup KM, Tucker TJ, Brady SF, Sisko JT, Naylor-Olsen AM, Lewis SD, Lucas BJ, Vacca JP: Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J Med Chem (1998) 41:1011-1013.
35. Maduskuie JrTP, McNamara KJ, Ru Y, Knabb RM, Stouten PFW: Rational design and synthesis of novel, potent bisphenylamidine carboxylate factor Xa inhibitors. J Med Chem (1998) 41:53-62. Convergent design of a nanomolar factor Xa inhibitor.
36. Kick EK, Roe DC, Skillman AG, Liu G, Ewing TJA, Sun Y, Kuntz ID, Ellman JA: Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsïn D. Chem e/b/(1997) 4:297-307.
37. Rockwell A, Melden M, Copeland RA, Hardman K, Decicco CP, DeGrado WF: Complementarity of combinatorial chemistry and structure-based ligand design: application to the discovery of novel inhibitors of matrix metalloproteinases. J Am Chem Soc (1996) 118:1033710338.
38. Norman TC, Gray NS, Koh JT, Schultz PG: A structurebased library approach to kinase inhibitors. J Am Chem Soe(1996) 118:7430-7431.
39. Smith PW, Solus SL, Howes PD, Cherry PC, Starkey ID, Cobley KN, Weston H, Scicinski J, Merritt A, Wellington A, Wyatt P, Taylor N, Green D, Bethell R, Madar S, Fenton RJ, Morley PJ, Pateman T, Beresford A: Dihydropyrancarboxamides related to Zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. J Med Chem (1998) 41:787-797.
40. Taylor NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J: Dihydropyrancarboxamtdes related to Zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides. J Med Chem (1998) 41:798-807.
41. Rice RL, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P, Lazo JS: A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry (WZJ) 36:15965-15974.
42. Combs AP, Kapoor TM, Feng S, Chen JK, Daudé-Snow LF, Schreiber SL: Protein structure-based combi-natorial chemistry: discovery of non-peptide binding elements to Src SH3 domain. JAm Chem S0e(1996) 118:287-288.
43. Feng S, Kapoor TM, Shirai F, Combs AP, Schreiber SL: Molecular basis for the binding of SH3 ligands with nonpeptide elements identified by combinatorial synthesis. Chem fife/(1996) 3:661-670.
44. Harada T, Katada J, Tachiki A, Asari T, lijima K, Uno I, Ojima I, Hayashi Y: Development of the new potent non-peptide Gpllb/llla antagonist NSL-95301 by utilizing combinatorial technique. BioorgMedChem £ert(1997)7: 209-212.
45. Corbett JW, Graciani NR, Mousa SA, DeGrado WF: Solidphase synthesis of a selective α,β, integrin antagonist library. Bioorg Med Chem Lett {1997) 7:1371 -1376.
46. Katz BA, Finer-Moore J, Mortezaei R, Rich DH, Stroud RM: Episelection: Novel K, - nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. Biochemistry(1995) 34: 8264-8280.
47. Selection and self-assembly of boronic add esters at the trypsin binding site.
48. Hue l, Lehn JM: Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc Natl Acad Sei USA (1997) 94: 21 OB2110.
49. Highly interesting concept of the self-assembly of inhibitors from molecular fragments at the binding site of a protein; proof of concept by the enzyme-induced formation of carbonic anhydrase inhibitors.
50. Katz BA, Clark, JM, Rner-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM: Design of potent selective zinc-mediated serine protease inhibitors. Nature (1998) 391:608-612.
51. Coleman DE, Berghuis AM, Lee E, Under ME, Oilman AG, Sprang SR: Structures of active conformations of Gia, and the mechanism of GTP hydrolysis. Science (1994) 265:1405-1412.
52. Sondek J, Lambright DG, Noel JP, Hamm HE, Sigler PB: GTPase mechanism of G proteins from the 1.7-A crystal structure of transducin ct.GDP.AIFJ. Nature (1994) 372:276-279.
53. Xu YW, Moréra S, Janin J, Cherfils J: AIF3 mimics the transition state of protein phosphorylation in the crystal structure of nucleoside diphosphate kinase and MgADP. Proc Natl Acad Sei USA (1997) 94:3579-3583.
54. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 274:1531-1534.
55. Key reference to the SA R by NMR technique.
56. Hajduk PJ, Meadows RP, Fesik SW: Discovering highaffinity ligands for proteins. Science (1997) 278:497-499. Overview of se veral different NMR techniques.
57. Hajduk PJ, Sheppard G, Nettesheim DQ, Olejniczak ET, Shuker SB, Meadows RP, Steïnman DH, Carrera Jr GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW: Discovery of potent nonpeplide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc(1997) 119:5818-5827.
58. Describes a six-month program to discover a nanomolar ligand of the matrix metalloproteinase, stromelysin (see Figure 2).
59. Olejniczak ET, Hajduk PJ, Marcotte PA, Netlesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW: Stromelysin inhibitors designed from weakly bound fragments: effects of linking and cooperativity. JAm Chem Soc(1997) 119:5828-5832. Discusses the cooperative effects of untethered ligands and the favorable influence of linking these fragments.
60. Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF, Fesik SW: NMR-based discovery of lead inhibitors that block DNA binding of the human PapillomavirusEZ protein. JMedChem(1997) 40:3144-3150
61. Hajduk PJ, Olejniczak ET, Fesik SW: One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J Am ChemSoc(1997) 119:12257-12261.
62. IJn M, Shapiro MJ, Wareing JR: Diffusion-edited NMRaffinity NMR for direct observation of molecular Interactions. JAm Chem Soc (1997) 119:5249-5250.
63. Lin M, Shapiro MJ, Wareing JR: Screening mixtures by affinity NMR. JOrg Chem(lQ97) 62:8930-8931.
64. LJepinsh E, Otting G: Organic solvents identify specific ligand binding sites on protein surfaces. Nature Biotechnol (1997)15:264-268.
65. Alien KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, Ringe D: An experimental approach to mapping the binding surfaces of crystalline proteins. J Phys Chem (1996) 100:2605-2611.
66. Mattos C, Ringe D: Locating and characterizing binding sites on proteins. NatureBiotechno/(1996) 14:595-599. Describes the multiple solvent crystal structure (MSCS) approach which uses different solvent molecules as probes to locate binding sites of proteins.
67. Höltje HD, Folkers G: Molecular Modeling. Basic principles and applications. VCH, Weinheim (1996). Application-oriented text book with special emphasis on small molecule modeling, pharmacophore generation, protein and ligandprotein complex modeling.
68. Bamborough P, Cohen FE: Modeling - protein-ligand complexes. CurrOpin Struct Bio/(1996) 6:236-241. Review of docking, de novo design and scoring functions.
69. Martin YC, Willett P (Eds): Designing bioactive molecules: three-dimensional techniques and applications. ACS Professional Reference Books, American Chemical Society, Washington (1998).
70. Several chapters cover computational techniques to process 3D structures of small molecules, 3D database searching, SAR by pharmacophore mapping and 3D QSAR, docking and de novo design.
71. Klebe G: Toward a more efficient handling of conformational flexibility in computer-assisted modeling of drug molecules. Persp Drug Discov Design (1995) 3:85-105.
72. Mestres J, Rohrer DC, Maggiora GM: MIMIC: a molecularfield matching program. Exploiting the applicability of molecular similarity approaches. J Comput Chem (1997) 18:934-954.
73. Mestres J, Rohrer DC, Maggiora GM: A molecular field based similarity approach to pharmacophoric pattern recognition. J Mol Graphics Mod(\Q°>7) 15:114-121.
74. Bohacek R, de Lombaert S, McMartin C, Priestle J, Grütter M: Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors. J Am Chem So? (1996) 118:8231-8249.
75. Maddalena DJ, Snowdon GM: Applications of genetic algorithms to drug design. Exp Opin Ther Patents (1997) 7:247-254. Comprehensive overview of the use of genetic and evolutionary algorithms in QSAR, molecular modeling, docking and de novo design (51 references).
76. Jones G, Willett P, Glen RC: A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J ComputAidedMol Design (1995) 9:532-549.
77. Lemmen C, Lengauer T: Time-efficient flexible superposition of medium-sized molecules. J Comput-Aided Mol Design (1997) 11:357-368. Efficient algorithm for the flexible superposition of a ligand onto a rigid template molecule, by decomposing the ligand into small rigid fragments that are re-assembled to a low-energy conformation which fits the template. A test version of the program is posted at http-J/cartan.defllex-bin/FlexS (Web address case sensitive).
78. Nissink JWM, Verdonk ML, Kroon J, Mietzner T, Klebe G: Superposition of molecules: electron density fitting by application of Fourier transforms. J Comput Chem (1997) 18:638-645
79. Lengauer T, Rarey M: Computational methods for biomolecular docking. Curr Opin Struct S/b/(1996) 6:402406.
80. Review of ligand-protein and protein-protein docking (46 references).
81. Clark DE, Westhead DR: Evolutionary algorithms in computer-aided molecular design. J Comput-Aided Mol Design (1996) 10:337-358. Comprehensive review on the use of evolutionary and genetic algorithms in conformatlonal search, molecular docking, de novo design, receptor modeling and various other modeling applications (226 references).
82. Ewing TJA, Kuntz ID: Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem (1997) 18:1175-1189. Describes various improvements of the DOCK program incorporated in the DOCK version 4.0.
83. Knegtel RMA, Kuntz ID, Oshiro CM: Molecular docking to ensembles of protein structures. JMolBiol'(1997) 266:424440.
84. Gschwend DA, Sirawarapom W, Santi DV, Kuntz ID: Specificity in structure-based drug design - identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Proteins (1997) 29:59-67.
85. Goodford P: Multivariate characterization of molecules for QSAR analysis. J Chemometrics (1996) 10:107-117. Description of the GRID program, force field and method for the calculation of intermolecular interaction energies.
86. De Rosa MC, Berglund A: A new method for predicting the alignment of flexible molecules and orienting them in a receptor cleft of known structure. J Med Chem (1998) 41:691-698.
87. Rarey M, Kramer B, Lengauer T, Klebe G: A fast flexible docking method using an Incremental construction algorithm. JMoIBio!(1QQG) 261:470-489. Efficient algorithm for the flexible docking of a ligand onto a rigid protein surface by decomposing the ligand into small rigid fragments that are re-assembled to a low-energy conformation which fits the binding site (see Figure 3). A test version of the program is posted at http-J/cartan.de/flex-bin/FlexX (Web address case sensitive).
88. Lengauer T: The FLEX approach: an alternative for receptor-ligand docking and computing crystal conformations. In: Computer-Assisted Lead Finding and Optimization (Proceedings of the 11l" European Symposium on Quantitative Structure-Activity Relation-ships, Lausanne, 1996), van de Waterbeemd H, Testa B, Folkers G (Eds). Verlag Helvetica Chimica Acta and VCH, Basel and Weinheim (1997):397-420. See reference [74]
89. Rarey M, Wefing S, Lengauer T: Placement of mediumsized molecular fragments into active sites of proteins. J Comput-Aided Mol Design (1996) 10:41-54.
90. Rarey M, Kramer B, Lengauer T: Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J Comput-Aided Mot Design (1997) 11:369-384.
91. Jones G, Willett P, Glen RC, Leach AR: Development and validation of a genetic algorithm for flexible docking. J Afo/5/b/(1997) 267:727-748.
92. Describes the program GOLD (distributed by the Cambridge Crystallographic Data Centre, Cambridge, UK) for flexible ligand docking. For more information, see httptfwww.ccdc.cam.ac.uk/ prods/gold.html.
93. Makino S, Kuntz ID: Automated flexible ligand docking method and its application for database search. J Comput Chem (1997) 18:1812-1825. DOCK version for flexible ligand docking; follows the FlexX strategy.
94. a Westhead DR, Clark DE, Murray CW: A-comparison of heuristic search algorithms for molecular docking. J Comput-Aided Mol Design (1997) 11 -.203-228. b. McMartin C, Bohacek, RS: QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput-Aided Mol Design (1997) 11:333-344.
95. Dixon JS: Evaluation of the CA5P2 docking section. Proteins (1997) Supp/1:198-204. 777/5 article and the following four references [82-85] describe the performance of different docking programs that were presented at the Second Meeting on the Critical Assessment of Techniques for Protein Structure Prediction (CASP2), held in Asilomar, CA, USA, December 13-16, 1996.
96. Hart TN, Ness SR, Read RJ: Critical evaluation of the Research docking program for the CASP2 challenge. Proteins (1997) Suppl 1:205-209.
97. Sobolev V, Moailem TM, Wade RC, Vriend G, Edelman M: CASP2 molecular docking predictions with the LIGIN software. Proteins (1997) Supp/1:210-214.
98. Totrov M, Abagyan R: Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins (1997) Suppl 1:215-220.
99. Kramer B, Rarey M, Lerigauer T: CASP2 experiences with docking flexible ligands using FlexX. Proteins (1997) Suppl 1:221-225.
100. Müller K (Ed): De novodesign. Persp Drug Discov Design (1995)3:1-209. Special PD3 issue on computer-aided drug design (10 chapters).
101. Böhm HJ: Computational tools for structure-based ligand design. Prog Biophys Molec Biol (\99Q) 66:197-210. Detailed review on current computational methods for computerassisted lead discovery (106 references).
102. Böhm HJ: Current computational tools for de novo ligand design. CurrOpinBfotechno/(1996)7:433-436. Short review on solved and unsolved problems in de novo drug design.
103. Marrone TJ, Briggs JM, McCammon JA: Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol (\997) 37:71-90. Review of the discovery of lead compounds by computer-aided design, scoring functions and free energy perturbation calculations (104 references).
104. Parrill A: Recent advances in computer-aided drug design methods. Exp Opin Ther Patents (1997) 7:937-945. Short review on new techniques, focusing on patented methods (52 references and 30patent references).
105. Böhm HJ: Towards the automatic design of synthetically accessible protein ligands: peptides, amides and peptidomimetics. J Comput-Aided Mol Design (1996) 10:265-272.
106. Böhm HJ: Combinatorial docking. In: Computer-Assisted Lead Finding and Optimization (Proceedings of the 11" European Symposium on Quantitative Struclure-Activity Relationships, Lausanne, 1996), van de Waterbeemd H, Testa B, Folkers G (Eds). Verlag Helvetica Chimica Acta and VCH, Basel and Weinheim (1997):123-133.
107. Caflisch A, Karplus M: Computational combinatorial chemistry for de novo ligand design: review and assessment. Persp Drug Discov Design (1995) 3:51-84. Describes the MCSS (multiple copy simultaneous search) method for ligand design and its assessment by the design of thrombin inhibitors.
108. Caflisch A, Ehrhardt C: Structure-based combinatorial ligand design. In: Structure-based drug design, Veerapandian P (Ed). Marcel Dekker, New York (1997):541558.
109. Joseph-McCarthy D, Hogle JM, Karplus M: Use of the multiple copy simultaneous search (MCSS) method to design a new class of Picornavirus capsld binding drugs. Proteins (1997) 29:32-58.
110. Ruppert J, Welch W, Jain AN: Automatic identification and representation of protein binding sites for molecular docking. Protein Science (1997) 6:524-533.
111. Böhm HJ, Klebe G: What can we learn from molecular recognition In protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl(1996) 35:2589-2614. Detailed review of ligand-prolein interactions, binding modes of ligands, structure-based and computer-aided drug design (279 references).
112. Bruno IJ, Cole JC, Lommerse JPM, Rowland RS, Taylor R, Verdonk ML: IsoStar: a library of information about nonbonded interactions. J Comput-Aided Mol Design (1997)11:525-537. Program for the visualization of non-bonded interactions between molecules, extracted from the Cambridge Structural Database (distributed by the Cambridge Crystallographic Data Centre, Cambridge, UK). For more information, see http-J/v/ww.ccdc. cam.ac.uk/prods/i sostar.html.
113. Wang H, Ben-Nairn A: A possible involvement of solventinduced interactions in drug design. J Med Chem (1996) 39:1531-1539.
114. Ladbury JE: Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem 5/o/(1996) 3:973-980.
115. Ajay, Murcko MA: Computational methods to predict binding free energy in ligand-receptor complexes. J Med Chem (1995) 38:4953-4967. Excellent review on various scoring functions (90 references).
116. Jain AN: Scoring noncovalent protein-ligand interactions: a continuous ditferentiable function tuned to compute binding affinities. J Comput-Aided Mol Design (1996) 10:427440. Fast and accurate scoring function with additional terms for entropie andsolvation effects.
117. Gilson MK, Given, JA, Head MS: A new class of models for computing receptor-ligand binding affinities. Chem Biol (1997)4:87-92.
118. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP: Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput-Aided Mol Design (1997) 11:425-445.
119. LJIjefors T: Progress in force-field calculations of molecular interaction fields and intermolecular interactions. In: 3D QSAR in drug design. Volume 2. LJgandprotein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):3-17.
120. Wade RC, Ortiz AR, Gago F: Comparative binding energy analysis. In: 3D QSAR in drug design. Volume 2. LJgandprotein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):19-34.
121. Oprea Tl, Marshall GR: Receptor-based prediction of binding affinities. In: 3D QSAR in drug design. Volume 2. LJgand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):35-61.
122. Holloway MK: A priori prediction of ligand affinity by energy minimization. In: 3D OSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):63-84.
123. Reddy MR, Viswanadhan VN, Erion MD: Rapid estimation of relative binding affinities of enzyme Inhibitors. In: 3D
124. OSA R in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):85-98.
125. Knegtel RMA, Grootenhuis PDJ: Binding affinities and nonbonded interaction energies. In: 3D OSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):99-114.
126. Weber IT, Harrison RW: Molecular mechanics calculation on protein-ligand complexes. In 3D OSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):115-127.
127. Hubbard RE: Can drugs be designed? Curr Opin Biotecfino/(1937) 8:696-700. Review of the successful use of rational structure-based approaches in drug discovery (43 references).